Discontinued Operations - Schedule of discontinued operation in operations statement (Details)	12 Months Ended
	Dec. 31, 2023 USD ($)
Discontinued operation operating expense
Gain on sale of discontinued operations	$ 1,467,451
Net loss from discontinued operations before income taxes	(5,005,518)
Income tax expense	(65,189)
Net loss from discontinued operations	(5,070,707)
Discontinued Operations, Disposed of by Sale | Elusys Therapeutics business unit
Discontinued Operations
Revenue	6,699,200
Discontinued operation operating expense
Cost of revenues	2,163,723
Research and development	2,549,959
Selling, general and administrative	1,346,565
Amortization of intangible assets	1,091,250
Goodwill impairment loss	3,873,079
Intangible asset impairment loss	2,277,921
Change in fair value of contingent consideration	(107,355)
Total operating expenses	13,195,142
Loss from operations	(6,495,942)
Gain on sale of discontinued operations	1,467,451
Interest income	55,991
Other expense	(33,018)
Total non-operating gain	1,490,424
Net loss from discontinued operations before income taxes	(5,005,518)
Income tax expense	(65,189)
Net loss from discontinued operations	$ (5,070,707)